Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $223.8352W HIGH $386.00
Volume
437.98 K
Value Traded
202.25 M
Short % Float
3.4%
+0.4%Week
+8.51%1 Month
+2.47%3 Month
+41.75%6 Month
-5.27%5 Year
+28,422.37%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
25.79 B
EPS (TTM)
8.03
P/E Ratio
45.66
Ent. Value
25.56 B
Total Shares
70.38 M
Float Shares
69.85 M
Insiders
0.75%
Institutions
102.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
WST Catalyst Timeline
Dated clinical, regulatory and corporate events for West Pharmaceutical Services, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for West Pharmaceutical Services, Inc.
1Total events
0Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
▲Partnership / LicenseCorporate
Completed sale and transfer of manufacturing and supply rights for SmartDose 3.5mL On-Body Delivery System
Past FDA Catalysts and PDUFA Decisions
How WST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
West Pharmaceutical Services, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every WST program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Favorite Annette FOfficer (Sr. VP & Chief HR Officer) | Option | 2,524 24,341.81 held | $89.64 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in WST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.5 % | 25.34 M | 70.60 K |
WST Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How WST ranks across every disease it competes in
Competitive Position is a premium feature
See how WST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialWST News
WST▼ -1.7%today
West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
West Pharmaceutical Services, Inc. will participate in CPHI Worldwide in Milan, Italy, to showcase its leadership in drug packaging and delivery solutions. The company will highlight its SelfDose® patient-controlled injector, which is powered by the West Synchrony® S1 prefillable syringe system. Additionally, West will conduct a technical presentation and panel discussion on drug-device development and patient choice dilemmas.
Read more →WSTWest to Participate in Upcoming Investor Conferences
West Pharmaceutical Services, Inc. (NYSE: WST) will present at two upcoming investor conferences: the Wells Fargo Annual Healthcare Conference on September 10, 2026, and the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026. Live webcasts will be available on the company's website, with replays accessible for 90 days post-event. West is recognized for its innovative injectable solutions and reported $3.07 billion in net sales for fiscal year 2025.
Read more →WSTWest Reports Second-Quarter 2026 Results
West Pharmaceutical Services, Inc. reported strong second-quarter results for 2026, with net sales of $872.3 million, reflecting a 13.8% increase compared to the previous year. The company also raised its full-year guidance for net sales and adjusted-diluted EPS, driven by robust performance in its High Value Product Components segment. The CEO expressed satisfaction with the results and the company's outlook.
Read more →WSTWest Declares Quarterly Dividend
West Pharmaceutical Services, Inc. announced a quarterly dividend of $0.22 per share, payable on August 5, 2026. Shareholders of record as of July 29, 2026, will receive this dividend. The company continues to demonstrate strong financial performance, generating $3.07 billion in net sales for the fiscal year 2025.
Read more →WSTWest to Host Second-Quarter 2026 Conference Call
West Pharmaceutical Services, Inc. will release its second-quarter 2026 financial results on July 23, 2026, before the market opens. Following the release, a conference call will be held at 8:00 a.m. Eastern Time to discuss the results and future business expectations. Participants must register in advance to ask questions during the call.
Read more →WSTWest Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
West Pharmaceutical Services, Inc. has successfully completed the sale and transfer of manufacturing and supply rights for its SmartDose® 3.5mL On-Body Delivery System. The transaction closed on July 1, 2026, as planned. West will maintain its focus on developing other SmartDose products, including the 10mL version, ensuring ongoing innovation in injectable drug delivery.
Read more →WSTWest Appoints Michel Lagarde to be President and Chief Executive Officer
West Pharmaceutical Services has appointed Michel Lagarde as the new President and CEO, effective August 31, 2026. Lagarde succeeds Eric M. Green, who will retire from his roles. The transition also includes Robert F. Friel becoming Board Chair. Lagarde aims to enhance the company's reputation and focus on delivering innovative therapies in the evolving life sciences industry.
Read more →WST▲ +12.9%on this newsshared move
West Reports First-Quarter 2026 Results -Strong Start to the Year and Raising Full Year Revenue and EPS guidance
West Pharmaceutical Services, Inc. reported a strong performance for the first quarter of 2026, with net sales of $844.9 million, a 21% increase year-over-year. The company also raised its full-year revenue guidance to between $3.295 billion and $3.350 billion and adjusted diluted EPS guidance to a range of $8.40 to $8.75. Notable growth was observed in the High-Value Products Components segment, driven by significant demand for GLP-1 and non-GLP-1 products. The outlook for the second quarter appears optimistic, with anticipated net sales between $830 million and $850 million.
Read more →WST▲ +12.9%on this newsshared move
West Reports First-Quarter 2026 Results
West Pharmaceutical Services, Inc. reported a strong financial performance for the first quarter of 2026, with net sales of $844.9 million, a 21% increase year-over-year. The company raised its full-year revenue and EPS guidance due to robust demand, particularly in its High Value Products Components segment. The adjusted-diluted EPS increased significantly by 46.9% to $2.13. Management expressed optimism about continued growth momentum.
Read more →WSTWest to Host First-Quarter 2026 Conference Call
West Pharmaceutical Services, Inc. will announce its first-quarter 2026 financial results on April 23, 2026. A conference call is scheduled for 8:00 a.m. Eastern Time to discuss these results and future business expectations. Participants can register in advance to ask questions during the call, which will also be available for replay on the company's website.
Read more →WSTWest Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
West Pharmaceutical Services has opened a new 165,000 square foot facility in Dublin to enhance its contract services for high-volume injectable therapies, particularly for diabetes and obesity. This expansion aims to meet the increasing global demand for complex drug delivery systems. The facility will support advanced automation and expanded drug-handling capabilities, reinforcing West's commitment to providing reliable drug delivery solutions.
Read more →WSTEric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc. West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from...
Eric M. Green, President, CEO, and Chair of West Pharmaceutical Services, Inc. (WST), plans to retire once his successor is appointed, expected in the second half of 2026. His tenure of over eleven years saw significant revenue growth and a total shareholder return of roughly 350%. The Board is currently engaging an executive recruiting firm to facilitate the transition. Despite the leadership change, the company reaffirms its guidance and remains optimistic about its long-term growth and innovation capabilities.
Read more →WSTWest Announces Quarterly Dividend and Share Repurchase Program - February 17, 2026
West Pharmaceutical Services, Inc. announced a quarterly dividend of $0.22 per share, payable on May 6, 2026. Additionally, the company has authorized a new share repurchase program for up to $1 billion of its common stock. The timing and number of shares repurchased will depend on market conditions and other factors.
Read more →WSTWest Announces Quarterly Dividend and Share Repurchase Program
West Pharmaceutical Services, Inc. announced a quarterly dividend of $0.22 per share, payable on May 6, 2026. Additionally, the Board of Directors authorized a new share repurchase program for up to $1 billion. The timing and number of shares repurchased will depend on various market factors. The previous repurchase program was fully utilized before its expiration.
Read more →WSTWest Reports Fourth-Quarter and Full-Year 2025 Results
West Pharmaceutical Services, Inc. reported strong financial results for Q4 and full year 2025, driven by significant growth in its High-Value Product Components segment. The company anticipates continued positive momentum into 2026, with a focus on operational excellence. However, challenges remain in the healthcare diagnostic devices market.
Read more →WSTWest to Host Fourth-Quarter and Full-Year 2025 Conference Call
West Pharmaceutical Services, Inc. will release its fourth-quarter and full-year 2025 financial results on February 12, 2026. A conference call will follow at 8:00 a.m. Eastern Time to discuss these results and future business expectations. Participants can register in advance to ask questions during the call.
Read more →About West Pharmaceutical Services, Inc.
Headquarters530 HERMAN O. WEST DRIVE, EXTON, PA, 19341
BIOPHARMAWATCH ELITE PLUS
Trade the next WST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime